Investor Presentaiton
Voice & Respiratory Care delivered 9% organic growth in Q2 with solid
momentum in both Laryngectomy and Tracheostomy
Voice & Respiratory Care performance
9
9
6
6
9
13
480
479
459
446
298
Q2 21/22
Q3 21/22
Q4 21/22
Q1 22/23 Q2 22/23
Revenues (DKKm)
Organic growth (%)
Acquired growth impact (%)
•
•
Q2 2022/23 highlights
February 1, 2023, marked the one-year anniversary of the completion of the
Atos Medical acquisition. The business has continued to perform in line with
expectations (8-10% organic growth). The integration into Coloplast's
infrastructure is also progressing well and on track to plan
Voice and Respiratory Care delivered 9% organic growth (2 months)
•
•
Laryngectomy delivered high single-digit organic growth, driven by
growth in new patients in existing and new markets, as well as an
increase in patient value driven by the Provox® Life™ portfolio
Tracheostomy and ENT (Ear, Nose & Throat) delivered double-digit
organic growth, with continued solid demand and positive impact
from forward integration in key European markets
All regions contributed to growth led by Europe and a solid contribution from
the US. In Emerging markets, Poland made a solid contribution to growth as
a result of a newly introduced reimbursement scheme for HMES, following a
four-year long market access project aimed at raising the standard of care
for laryngectomy patients
In April, Atos Medical announced the results of a new clinical study
demonstrating significant improvement in pulmonary health and related
symptoms when using Provox Life*
8
*Provox Life Ward - Atos Medical
ColoplastView entire presentation